Ace Therapeutics
Ace Therapeutics is a preclinical contract research provider dedicated to offering comprehensive one-stop services. Our expertise spans across various preclinical services, including efficacy testing, pharmacokinetics, toxicology, and biomarker development, to support clients in their research and development efforts.
With a team of experienced researchers and state-of-the-art facilities, we aim to support the development of innovative therapies. From early-stage research to preclinical studies, we provide tailored solutions that help advance drug development processes. Our expertise, cutting-edge technology, and commitment to quality ensure that we deliver reliable and efficient preclinical services to meet the needs of our clients.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Genesis Research Group
Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…
Company Details
Latest Content from PMHub
What 90 Minutes of Live AI Case Practice Revealed About Physician Readiness
Press Releases | October 12, 2026 | Medscape Education
At EHA 2026 in Stockholm, 425 hematologists and oncologists attended an independent, 90-minute Medscape symposium on the practical and ethical use of AI. The format was case-based. The faculty presented...
On GLOBE Final Rule
Press Releases | October 9, 2026 | Genesis Research Group
The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally....
Rethinking Prenatal Migraine Management: The Clinical Case for Neuromodulation
Press Releases | October 8, 2026 | Medscape Education
Disclaimer: Management of migraine in pregnancy typically combines lifestyle strategies, nonpharmacologic approaches, selected pharmacologic options when benefits outweigh risks, and, increasingly, noninvasive neuromodulation technologies.
Pharma leadership strategies for talent, AI adoption, and continuous learning
White Papers and Resources | October 8, 2026 | Inizio
In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...
Invited, but not equipped: patient involvement needs more than an open door
White Papers and Resources | October 8, 2026 | Cuttsy + Cuttsy
Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.
Advancing the Frontier of Cancer Care: Medscape’s Mission at ESMO 2026
Press Releases | October 5, 2026 | Medscape Education
For more than 30 years, Medscape Education's dedication has been centered on a single goal: building independent, accredited oncology education that improves patient outcomes. This year, at the European Society...
Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.
Press Releases | October 2, 2026 | Genesis Research Group
On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.
Using AI Responsibly in CME Outcomes Reporting
Press Releases | October 1, 2026 | Medscape Education
ICYMI at #AIS2026: using AI in outcomes reporting is a lot like onboarding a research assistant. There's real efficiency in having the help, and a significant amount of background teaching,...
ANTHEM launches Healthy Influence – a new science-led approach to solve healthcare’s attention problem
Press Releases | October 1, 2026 | Resonant Group
Global healthcare communications consultancy ANTHEM, a Resonant Group company, today announces the launch of Healthy Influence™, its proprietary methodology that applies the science of influence to healthcare communications.
The outcomes are already chosen. So when can patients really shape them?
White Papers and Resources | September 29, 2026 | Cuttsy + Cuttsy
Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.